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Reportedly, complexes between factor XI and ADAMTS13  are detected with a com-
mercial ADAMTS13/FXI ELISA kit in plasma and are decreased in thrombotic throm-
bocytopenic purpura (TTP).  Using this kit, control and TTP patient plasma contained
varying amounts of signal (25-670% of a reference plasma) but no signal was
observed for mixtures of recombinant enzymes, suggesting little interaction.
ADAMTS13/FXI complexes were undetectable by immunoprecipitation or gel filtration
chromatography in control plasma or mixtures of recombinant proteins.  These results
suggest that ADAMTS13/FXI complexes are insignificant in plasma and unlikely to
affect the function of either protein during normal hemostasis or in TTP.
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ABSTRACT
ADAMTS13 cleaves von WillebrandFactor (VWF) to produce the distribu-tion of VWF multimer sizes character-
istic of normal plasma.1 Congenital or acquired
autoimmune deficiency of ADAMTS13 is
associated with the circulation of ultra-large
VWF (ULVWF) multimers and thrombotic
thrombocytopenic purpura (TTP).1-3 Recent
advances in clinical assay development have
led to several new methods for measuring
ADAMTS13 activity or ADAMTS13 antigen
levels.4-7 As more clinical assays are developed,
the mechanisms by which ADAMTS13
cleaves VWF are becoming better understood.  
Recently, a commercially available kit has
been used to demonstrate a complex between
coagulation factor XI (FXI) and ADAMTS13,
and since decreased levels of this complex are
proposed as a biomarker for TTP, a physical
interaction between the two proteinases must
therefore occur.  We have investigated the
occurrence of this complex using normal
human plasma, TTP patient plasma, FXI defi-
cient plasma, and recombinant proteins.  The
results indicate that measuring
FXI/ADAMTS13 complex is not useful for
evaluating patients with TTP.
Design and Methods
Citrated normal human plasma was
obtained from the American Red Cross, St.
Louis, MO, USA or from healthy volunteers
according to a protocol approved by the
Institutional Review Board of Washington
University in St. Louis. Polyclonal anti-
ADAMTS13 was prepared in rabbits (Poco-
no Rabbit Farm and Laboratory, Canadensis,
PA, USA) immunized with purified recombi-
nant human ADAMTS13.8 Recombinant
human FXI and ADAMTS13 were prepared
as previously described.9,10 Single chain high
molecular weight kininogen (HK) was pur-
chased from Enzyme Research Labs. FXI
deficient plasma was purchased from George
King Biomedical (Lot 1122-N23e1, contain-
ing <0.1% of FXI by ELISA), and aPTT
reagent containing Kaolin was from Helena
Laboratories.  IMUBIND ADAMTS13 (#813)
and ADAMTS13/FXI ELISA (#811) kits were
purchased from American Diagnostica.
Co-immunoprecipitation of FXI and
ADAMTS13 was performed using either
normal plasma or recombinant enzymes.
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Plasma samples were diluted in buffer (50 mM Hepes,
pH 7.4, 0.15 M NaCl), and human serum albumin was
precleared with mouse anti-HSA (1:500 of ascites,
Sigma) and protein G-Sepharose (1:10, GE Healthcare).
Immunoglobulins were further removed by incubation
with protein G-Sepharose (1:10).  FXI and ADAMTS13
were immunoprecipitated from the pre-cleared samples
using either monoclonal anti-human FXI (1G5.12, 1.6
µg/mL, final concentration)10 or monoclonal anti-human
ADAMTS13 (5C11, 4.6 µg/mL, final concentration)11
and protein G-Sepharose (1:10). Recombinant FXI,
ADAMTS13, or mixtures of the proteins, were
immunoprecipitated similarly but without pre-clearing
of albumin or immunoglobulins. Protein G-immunopre-
cipitates were washed three times and eluted by boiling
in reducing Laemmli buffer for 5 min.12 Samples were
electrophoresed by SDS-PAGE and electroblotted onto
polyvinylidene difluoride membranes.  FXI was detect-
ed with horseradish peroxidase (HRP) conjugated goat
anti-human FXI (0.8 µg/mL in casein blocking buffer,
Enzyme Research Labs). ADAMTS13 was detected
with rabbit anti-human ADAMTS13 (1:2,500 of ascites
in casein blocking buffer) followed by HRP-conjugated
swine anti-rabbit immunoglobulins (0.06 µg/mL in
casein blocking buffer, DAKO). Western blots were
developed using ECL plus reagent (GE Healthcare).
Chemifluorescence was detected using a STORM imag-
er and quantitated using ImageQuantTL software.9 Gel
filtration chromatography was performed using three
tandemly linked Bio-Sil SEC 250 columns (7.5 X 200
cm) attached to a Varian ProStar HPLC and equilibrated
in buffer A (50 mM Hepes, pH 7.4, 0.3 M NaCl), at 0.5
mL/min with 0.5 mL fractions collected.  Columns were
calibrated with standards ranging from 1.35 to 670 kDa
(BioRad), and supplemented with catalase (232 kDa, GE
Healthcare). Chromatography was performed by load-
ing ADAMTS13, FXI, or a combination of the two pro-
teins at the same concentration.  ADAMTS13 and FXI
activities were determined for each fraction to establish
retention volumes. ADAMTS13 activity was detected
using a fluorogenic peptide substrate, FRETS-VWF72,
consisting of the VWF sequence Arg1597-Arg1668 with the
mutation N1610C. The amino-terminus was labeled
with QSY 21 succinimidyl ester and the mutated Cys1610
was labeled with Alexa Fluor 594 C5 maleimide
(Molecular Probes).  Fluorescence intensities were meas-
ured as previously described9 on a Perkin Elmer
Victor2V using a 590 nm excitation filter (7 nm band
pass) and a 615 nm emission filter (10 nm band pass).
Concentrations of ADAMTS13 were determined by
comparison of the measured initial rate to the initial rate
for known concentrations of ADAMTS13.  FXI activity
was detected using the aPTT assay as described,10
except that 75 µL of each reagent was used.  Clotting
times were compared to a standard curve prepared
using dilutions of pooled normal plasma (American Red
Cross).
Results and Discussion
The IMUBIND ADAMTS13/FXI ELISA detected a
varying amount of apparent ADAMTS13/FXI complex
in normal plasma from different sources. Compared to
the manufacturer’s standard plasma supplied with the
kit (defined as 100%), American Red Cross plasma (3
units pooled) contained 560-670% of ADAMTS13/FXI
complex, and citrated plasma pooled from six volun-
teers contained 36-110% of ADAMTS13/FXI complex.
Three idiopathic TTP patient plasmas (<5%
ADAMTS13 activity)13 showed different amounts of
apparent ADAMTS13/FXI complex (25%, 31%, and
79% ADAMTS13/FXI complex) when compared with
the manufacturer’s standard. In addition, a FXI deficient
plasma yielded a value of 13% ADAMTS13/FXI com-
plex. In normal plasma, the ADAMTS13 antigen con-
centration determined with the IMUBIND ADAMTS13
antigen assay (0.9-1 µg/mL) was similar to values previ-
ously reported.14, 15 The TTP patient plasmas varied in
their ADAMTS13 antigen levels using the IMUBIND
ADAMTS13 antigen kit (0.4, 0.5, and 0.8 µg/mL)13, and
the FXI deficient plasma contained 0.5 µg/mL of
ADAMTS13.  The results suggest a high degree of vari-
ability in the concentration of ADAMTS13/FXI com-
plex detected using the IMUBIND ADAMTS13/FXI
ELISA kit in both normal and TTP patient plasma.
Congenitally-deficient FXI plasma cannot contain any
ADAMTS13/FXI complex but gave a substantial signal
in the IMUBIND ADAMTS13/FXI ELISA, indicating
that the assay method may not be specific for the
ADAMTS13/FXI complex.
ADAMTS13/FXI complex occurrence was further
investigated by immunoprecipitation with well-charac-
terized monoclonal antibodies.  When ADAMTS13 was
immunoprecipitated from normal plasma with anti-
ADAMTS13, co-immunoprecipitation of FXI was
essentially undetectable (Figure 1A, lanes 9-12).
Conversely, immunoprecipitation of FXI with anti-FXI
did not co-immunoprecipitate ADAMTS13 (Figure 1A,
lanes 1-4).  Control experiments showed that each anti-
body recognized only the corresponding recombinant
protein (Figure 1A) confirming the specificity of the
antibodies.  
Factor XI circulates in plasma as a complex with HK,16
suggesting that HK could be involved in binding to
ADAMTS13. Further studies using recombinant
ADAMTS13 and FXI in the presence and absence of HK
demonstrated no co-immunoprecipitation with either
antibody (Figure 1B). This suggests that little, if any,
interaction occurs between ADAMTS13, FXI, or HK. 
Interaction between ADAMTS13 and FXI might not
be detected by immunoprecipitation if complex forma-
tion interfered with monoclonal antibody binding or
vice versa. Therefore, the interaction was further inves-
tigated using gel filtration chromatography.
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Recombinant ADAMTS13 alone eluted near catalase
(232 kDa,  Figure 2A). The relatively early elution of
ADAMTS13 upon gel filtration chromatography indi-
cates that ADAMTS13 is asymmetric in solution under
these conditions.17 FXI eluted slightly earlier than IgG
(158 kDa, Figure 2B), similar to previous results.18 When
ADAMTS13 and FXI were chromatographed together
their elution positions were unchanged (Figure 2C).
The absence of a new peak with a shorter retention
time confirms that ADAMTS13 and FXI do not bind sig-
nificantly to each other, even when mixed at concentra-
tions of ~1.2 µM which is much higher than the normal
plasma concentration of ADAMTS13 (~5 nM)14,15 and
FXI (~30 nM).16 
The variability in the results obtained with different
sourced normal plasmas, as well as TTP patient and the
congenitally-deficient FXI plasmas, suggests that, in
general, the ADAMTS13/FXI ELISA will not be useful
for evaluating patients with thrombotic microangiopa-
thy. Specific binding between ADAMTS13 and FXI was
not detectable by several other methods, with or with-
out HK, which indicates that the signals observed in the
ADAMTS13/FXI ELISA may represent a small amount
of non-specific binding that is brought out by an espe-
cially sensitive ELISA design. Alternatively, the
ADAMTS13/FXI ELISA may possibly detect an uniden-
tified plasma component other than HK that simultane-
ously binds small amounts of ADAMTS13 and FXI
bound together in a larger complex.  However, failure to
observe significant binding between ADAMTS13 and
FXI suggests that a complex between these two proteins
is unlikely to play a role in normal hemostasis or in the
pathophysiology of TTP.
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Complexes of ADAMTS13 and FXI
Figure 1. Immunoprecipitation of ADAMTS13 and FXI. (A) Plasma
diluted 1:10 (v/v) (lanes 1, 2, 9, and 10) or 1:5 (v/v) (lanes 3, 4, 11
and 12) was incubated with anti-FXI (lanes 1, 3, 9, and 11) or anti-
ADAMTS13 (lanes 2, 4, 10 and 12) and antibody:antigen complex-
es were precipitated using protein G-Sepharose.  Similarly, recombi-
nant FXI (5.6 nM) (lanes 5, 6, 13, and 14) or recombinant
ADAMTS13 (5 nM) (lanes 7, 8, 15 and 16) were incubated with anti-
FXI (lanes 5, 7, 13, and 15) or anti-ADAMTS13 (lanes 6, 8,14, and
16) and immunoprecipitated using protein G-Sepharose. (B)
Recombinant FXI (5.6 nM) (lanes 1, 2, 9 and 10) and ADAMTS13 (5
nM) (lanes 3, 4, 11, and 12) alone were immunoprecipitated with
either anti-FXI (lanes 1, 3, 9, and 11) or anti-ADAMTS13 (lanes 2, 4,
10, and 12).  Combinations of recombinant FXI and ADAMTS13 in
the absence (lanes 5, 6 13, and 14) or presence (lanes 7, 8, 15, and
16) of HK (8 nM) were immunoprecipitated with either anti-FXI
(lanes 5, 7, 13 and 15) or anti-ADAMTS13 (lanes 6, 8, 14, and 16).
In each panel, the left panel was probed with anti-ADAMTS13, while
the right panel was probed with anti-FXI. The band that appears at
~30 kDA is the reduced form of the IgG light chain.
Figure 2. Gel Filtration Chromatography of ADAMTS13 and FXI.
ADAMTS13 (0.1 mg, dashed line) (A), FXI (0.1 mg, solid line) (B),
and combination of the two proteins (C) were chromatographed on
Bio-Sil SEC 250. Molecular weight standards, indicated by the
arrow heads (t), eluted in the following order: thyroglobulin (670
kDa), catalase (232 kDa), IgG (158 kDa), ovalbumin (44 kDa), myo-
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